DEXPROPRANOLOL HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H21NO2.ClH
Molecular Weight	295.804
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DEXPROPRANOLOL HYDROCHLORIDE

Structure Search

SMILES

Cl.CC(C)NC[C@@H](O)COC1=C2C=CC=CC2=CC=C1

InChI

InChIKey=ZMRUPTIKESYGQW-PFEQFJNWSA-N

InChI=1S/C16H21NO2.ClH/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;/h3-9,12,14,17-18H,10-11H2,1-2H3;1H/t14-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H21NO2
Molecular Weight	259.3434
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19108278

(R)-(+)-Propranolol (also known as DEXPROPRANOLOL) is the less active enantiomer of propranolol and is an antagonist of the beta-adrenergic receptor. It is known, that propranolol had been used for myocardial infarction; arrhythmia, anxiety and some other disease, but adverse effects instigated the replacement by newer drugs.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 89 Target ID: CHEMBL2094118 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19108278	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2596

PubMed

Title	Date	PubMed
Barakol suppresses norepinephrine-induced inhibition of spontaneous longitudinal smooth muscle contractions in isolated rat small intestine.	2005-10-03	16043318
Insights into cyclodextrin interactions during sample stacking using capillary isotachophoresis with on-line microcoil NMR detection.	2005-09	16049945
Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients.	2005-08	16110851
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005-06	15962942
Activation of BK channels in GH3 cells by a c-PLA2-dependent G-protein signaling pathway.	2005-06	15647401
Catecholaminergic consolidation of motor cortical neuroplasticity in humans.	2004-11	15142961
[Psychosomatic ratios and their correction in the autonomic dysfunction of the sinus node].	2004	15584595
Solubilization of cationic drugs in lung surfactant.	2003-11	14661933
Renal mechanisms involved in stress-induced antinatriuresis and antidiuresis in rats.	2003-07	14972749
KCNQ1 and KCNH2 mutations associated with long QT syndrome in a Chinese population.	2002-12	12442276
The effect of various surfactants on the release rate of propranolol hydrochloride from hydroxypropylmethylcellulose (HPMC)-Eudragit matrices.	2002-11	12445567
Solubility, metastable zone width, and racemic characterization of propranolol hydrochloride.	2002-05-05	11968072
Enantioselective metabolism of propanolol in isolated hepatocytes prepared from untreated, PB- or 3-MC-pretreated rats.	2001-03-01	11279838
Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.	2001-02	11159817
Structural basis for enantiomer binding and separation of a common beta-blocker: crystal structure of cellobiohydrolase Cel7A with bound (S)-propranolol at 1.9 A resolution.	2001-01-05	11114249
Potentiation by aminoethylisothiourea of the extra-cellular Ca(2+) component of norepinephrine-induced contraction in rat femoral arteries.	2001-01-01	11137715
Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.	1999-12	10565843
The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias.	1968-09	19108278

Patents

Sample Use Guides

In Vivo Use Guide

in cats: received an intravenous infusion of (+)-propranolol at 0.5 mg/min exhibited a prompt return to sinus rhythm after a mean total dose of 6.5 + 0.9 mg/kg. The final heart rate was an average of 48 beats/min below the initial rate. The difference between the antiarrhythmic doses of (+)- and (- )-propranolol was statistically significant (P<0.01).

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:54:21 GMT 2025` Edited by `admin` on `Mon Mar 31 17:54:21 GMT 2025`
Record UNII	AB9DB0NX46
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PROPRANOLOL HYDROCHLORIDE, (R)-

Preferred Name

English

DEXPROPRANOLOL HYDROCHLORIDE

Official Name

English

NSC-757295

Code

English

(2R)-1-((1-METHYLETHYL)AMINO)-3-(NAPHTHALEN-1-YLOXY)PROPAN-2-OL HYDROCHLORIDE

Systematic Name

English

DEXPROPRANOLOL HCL

Common Name

English

AY-20694

Code

English

(+)-1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL HYDROCHLORIDE

Systematic Name

English

DEXPROPRANOLOL HYDROCHLORIDE [USAN]

Common Name

English

I.C.I. 47,319

Code

English

ICI-47319

Code

English

2-PROPANOL, 1-((1-METHYLETHYL)-AMINO)-3-(1-NAPHTHALENYLOXY)-, HYDROCHORIDE, (R)-

Common Name

English

AY-20,694

Code

English

Code System Code Type Description

FDA UNII

AB9DB0NX46